Cardiol Therapeutics Announced Milestone in MAVERIC Trial

Cardiol Therapeutics Inc. has achieved its initial enrolment goal of 110 patients for the MAVERIC trial, ahead of the original deadline. The trial's Steering Committee, following a blinded review, has recommended expanding the enrolment to 150 patients. This decision aims to maintain the statistical power necessary for the primary efficacy analysis due to fewer than expected pericarditis recurrences.

The reduced recurrence rate is viewed positively, suggesting the potential effectiveness of CardiolRx as seen in earlier studies. Although the trial remains blinded, the lower rate might be due to a low placebo recurrence rate. The enrolment expansion shifts the anticipated results readout from Q1/27 to mid-2027, with resources available to support operations until Q1/28.

First Berlin Equity Research has adjusted the price target for Cardiol Therapeutics from USD 7.50 to USD 7.40, reflecting the extended timeline and recent dilution from exercised warrants, yet retains a Buy recommendation.